# Investors ### H1 2026 Results Results for H1 2026 were published on **July 30, 2026**. The recording of Ipsen’s H1 2026 Results Call is now available on demand. [Watch the recording](/content/event/h1-2026/index.html) ### The latest highlights from Investor Relations Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more. 12 February 2026 [FY 2025 Results](/content/event/fy-results/index.html) 31 July 2025 [Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance](/content/press-release/ipsen-delivers-strong-results-in-the-first-half-of-2025-and-upgrades-its-full-year-guidance-3124645/index.html) 16 April 2025 [Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance](/content/press-release/ipsen-delivers-strong-sales-in-the-first-quarter-2025-and-confirms-its-full-year-guidance-3062256/index.html) 10 April 2025 [Q1 2025 sales update](/content/stories/general/q1-2025-sales-update/index.html) 13 March 2025 [Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s](/content/update/ipsen-announces-assigned-investment-grade-ratings-from-sp-global-ratings-and-moodys-3041865/index.html) 13 February 2025 [Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…](/content/press-release/ipsen-delivers-solid-results-in-2024-driven-by-strong-performance-across-all-therapeutic-areas-and-provides-guidance-for-2025-3025567/index.html) 12 January 2025 [J.P. Morgan Healthcare Conference](/content/event/j-p-morgan-healthcare-conference/index.html) ### Investing for growth We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets. Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress. Aymeric Le Chatelier EVP, Chief Financial Officer ### Ipsen's latest investor presentation Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Please find below Ipsen’s latest investor presentation, reflecting our most recent messaging and key updates on strategy, performance and pipeline. [Learn more](/content/wp-content/uploads/2026/04/Ipsen-Q1-2026-Investor-presentation-1.pdf) #### Strong results backed by innovation With total sales growth of over 9%*, we delivered strong results in 2024, and we’ve had a strong start to 2025. We are on track to build further momentum in our transformation, and to achieve our objectives for the year. *At constant exchange rate. [Download Ipsen's Annual Report](/content/annualreport/index.html) ### Pipeline Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across our three therapeutic areas of Oncology, Rare Disease and Neuroscience. [Learn more](/content/pipeline/index.html) #### Shareholder information We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure. [Learn more](/content/investors/shareholders-information/index.html) #### Regulated information Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information. [Learn more](/content/investors/regulated-information/index.html) ### Five-year stock information Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares. [Learn more](https://tools.euroland.com/investortools/f-ipn/bundle.html)